BiotechTube

Resmetirom + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH

Conditions

NASH, Cirrhosis, Liver

Trial Timeline

Aug 26, 2022 → Jan 1, 2027

NCT ID
NCT05500222

About Resmetirom + Placebo

Resmetirom + Placebo is a phase 3 stage product being developed by Madrigal Pharmaceuticals for NASH. The current trial status is active. This product is registered under clinical trial identifier NCT05500222. Target conditions include NASH, Cirrhosis, Liver.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT07335601Phase 2Active
NCT05500222Phase 3Active

Competing Products

20 competing products in NASH

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
AZD2693AstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
Tropifexor + LicogliflozinNovartisPhase 2
52
LMB763 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + PlaceboNovartisPhase 2
52
TRO19622 + PlaceboRochePhase 2
52
SEL + SIMGilead SciencesPhase 2
51
Seladelpar + PlacebosGilead SciencesPhase 2
51
Placebo + SIMGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32

Other Products from Madrigal Pharmaceuticals

MGL-3196 + PlaceboPhase 3
74
Placebo + ResmetiromPhase 3
74
ResmetiromPhase 3
74
Resmetirom + PlaceboPhase 2
49
MGL-3196 (resmetirom) + PlaceboPhase 2
49